Relationship of serum imatinib trough level and response in CML patients: Long term follow-up

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1573-1575

  Awidi, Abdalla ^a   Ayed, Ayed O ^a   Bsoul, Nazzal ^a   Magablah, Ahmad ^a   Mefleh, Razan ^a   Dweiri, Mohammad ^b   Ramahi, Mohammad ^b   Arafat, Eyad ^b   Bishtawi, Mohammad ^b   Marie, Lena ^c  

^a UNIVERSITY OF JORDAN   (Jordan)

^b Ministry of Health   (Jordan)

^c KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

CML; Imatinib; Leukemia; Molecular response; ROC analysis; Serum levels

Indexed keywords

IMATINIB;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; JORDAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; JORDAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; ROC CURVE;

EID: 78149357619     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.014     Document Type: Article

References (11)

1. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
2. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
3. Cortes J.E., Egorin M.J., Guilhot F., et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009, 23:1537-1544.
4. Hughes T.P., Branford S., White D.L., et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008, 112:3965-3973.
5. Uges D.R.A. Plasma or serum in therapeutic drug monitoring and clinical toxicology. Pharm World Sci 1988, 10:185-188.
6. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia; International Randomised Study of Interferon versus STI571 (IRIS) Study Group. N Engl J Med 2003, 349:1423-1432.
7. Awidi A., Salem I.I., Najib N., et al. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison. Leuk Res 2010, 34:714-717.
8. Peng B., Hayes M., Resta D., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004, 22:935-942.
9. White D.L., Saunders V.A., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110:4064-4072.
10. Li-Wan-Po A., Farndon P., Craddock C., Griffiths M. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol 2010, 66:369-374.
11. Blasdel C., Egorin M.J., Lagattuta T.F., et al. Therapeutic drug monitoring in CML patients on imatinib. Blood 2007, 110:1699-1701.